INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RCKT

Group 1 - The core issue involves a class action lawsuit against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading statements about the safety and clinical trial protocol of its gene therapy product RP-A501 [1][4][5] - The lawsuit claims that Rocket Pharmaceuticals failed to disclose serious adverse events, including patient deaths, during a Phase 2 clinical trial for Danon disease, which led to a significant drop in the company's stock price following the FDA's clinical hold announcement [4][5] - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, are eligible to seek appointment as lead plaintiff in the class action lawsuit [1][6] Group 2 - Rocket Pharmaceuticals is characterized as a late-stage biotechnology company focused on developing gene therapies for rare diseases [3] - The law firm Robbins Geller Rudman & Dowd LLP, known for its expertise in securities fraud litigation, is representing the investors in this class action case [7]